Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | DYRK2 | Q92630 | 9/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.55 |
| ▸ | PIM1 | P11309 | 8/20 | 0.52 |
| ▸ | DYRK3 | O43781 | 6/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 6/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.52 |
| ▸ | CSNK2A3 | Q8NEV1 | 6/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14181814 | 0.74 | ALDH1A1 (1.00) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL14358778 | 0.73 | ALDH1A1 (0.52) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL22275227 | 0.73 | ALDH1A1 (0.59) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL29369746 | 0.73 | GSK3B (0.83) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL1249098 | 0.73 | GSK3B (0.83) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL29763457 | 0.73 | MAPT (0.64) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL2882197 | 0.73 | GSK3B (0.83) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL10518776 | 0.73 | MAPT (0.64) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL10750926 | 0.73 | KMT2A (0.76) | MAPTALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL10750921 | 0.73 | KMT2A (0.76) | MAPTALDH1A1KMT2AKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022026-A1 | METHOD OF TREATING CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2012-01-26 | — | — | US | disclosed |
| EP-2387403-A1 | METHOD OF TREATING CANCER | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253692-A1 | Electrical heater for vehicle windshields and windows | SCHAUBLE RICHARD EGON | 2011-10-20 | — | — | US | disclosed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010082813-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20060134048-A1 | Reduction of hair growth | GILLETTE COMPANY, THE | 2006-06-22 | — | — | US | disclosed |
| US-20050249685-A1 | topical applying heat shock protein inhibitors | GILLETTE COMPANY, THE | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | MAPT 9/4885ALDH1A1 2348/4885KMT2A 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.